Nanocarry
Omri Amirav-Drory is a Board Member at Nanocarry. Omri has also worked with resistanceBio, Talus Bio, La Jolla Labs, Mana.bio, PANGEA Therapeutics, Pepper Bio, Nanocarry Therapeutics, Gilboa Therapeutics, and NFX in the past.
Omri Amirav-Drory received their Bachelor of Science in Biochemistry and Molecular Biology from Tel Aviv University. Omri then went on to earn their Doctor of Philosophy in Biochemistry from the same school. After completing their Ph.D., they did a postdoctoral fellowship in Biochemistry and Molecular Biology at Stanford University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Nanocarry
Nanocarry is developing a new class of therapeutics based on bioengineered nanoparticles with novel capabilities to treat oncology indications and brain diseases. Using a proprietary “Plug and Play” approach, Nanocarry’s AxS platform can be easily modified to deliver a wide array of biologics, safely and effectively, to the brain and beyond. Nanocarry’s first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer.